Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis

Amandeep K. Dhillon1,2,3, Andreas E. Kremer4, Martin Kummen1,2,3, Kirsten M. Boberg1,2,5, Ronald P. Oude Elferink6, Tom H. Karlsen1,2,3,5, Ulrich Beuers6, Mette Vesterhus1,7,8 & Johannes R. Hov1,2,3,5

Autotaxin has been associated with liver disease severity and transplant-free survival. This study aimed to validate autotaxin as a biomarker in two cohorts of Norwegian large-duct PSC patients, one discovery panel (n = 165) and one validation panel (n = 87). Serum activity of autotaxin was measured in diluted sera by a fluorometric enzymatic assay. Patients reaching an end-point, liver transplantation or death, (discovery panel: n = 118 [71.5%]; validation panel: n = 35 [40.2%]), showed higher autotaxin activity compared with the other patients, P < 0.001 and P = 0.004, respectively. Kaplan-Meier survival analyses showed a strong association between increasing autotaxin activity and shorter liver transplant-free survival (discovery panel: P < 0.001, validation panel: P = 0.001). There was no relationship between autotaxin activity and the presence of inflammatory bowel disease or occurrence of hepatobiliary malignancy. In a multivariable analysis, high autotaxin activity was associated with an increased risk of liver transplantation or death (hazard ratio 2.03 (95% confidence interval 1.21–3.40), P < 0.01), independent from Mayo risk score, an in-house enhanced liver fibrosis score and interleukin-8 in serum. In conclusion, increased serum autotaxin activity is associated with reduced liver transplant-free survival independent from Mayo risk score and markers of inflammation and fibrosis.

Primary sclerosing cholangitis (PSC) is a progressive inflammatory disease of the intra- and extrahepatic bile ducts, leading to strictures, cholestasis, cirrhosis and liver failure. There is no effective medical treatment available to retard the progression of PSC. Median time to liver transplantation is 13–21 years1. The disease is complicated by cholangiocarcinoma in 10–15% of the patients, which is an important clinical problem with dismal prognosis2. Pruritus is a common symptom in patients with cholestatic liver diseases, but the underlying mechanisms are poorly understood3. Autotaxin is an enzyme that hydrolyzes lysophospholipids into lysophosphatidic acid (LPA), which has been identified as a potential mediator of cholestasis-associated pruritus4. LPA is unstable and autotaxin activity in serum is used as surrogate marker of LPA levels5. Interestingly, autotaxin is overexpressed in some cancers and has been linked to both tumor cell proliferation6,7 and fibrosis8.

The disease activity in PSC patients shows large variations over the disease course, and there are few tools available to predict prognosis and measure response to treatment for the individual patient. We have previously identified several biomarkers of disease severity and prognosis in PSC reflecting different aspects of the disease process, like inflammation (IL-8)9, neutrophil activation (soluble CD14)10, fibrosis (enhanced liver fibrosis [ELF] score and pro-C3)11 and gut microbial activity12,13. Recently, autotaxin activity was described as a marker of severity of liver injury and survival in a study of a single cohort of patients with primary biliary cholangitis (PBC) and PSC14. Hence, in the present study we aimed to validate the predictive value of autotaxin activity in

1Norwegian PSC Research Center, Department of transplantation medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. 2Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3Division of Surgery, Inflammatory diseases and Transplantation, Oslo University hospital Rikshospitalet, Oslo, Norway. 4Department of Medicine 1, Friedrich-Alexander-University Erlangen-Nürnberg-Erlangen, Erlangen, Germany. 5Section of Gastroenterology, Department of Transplantation Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. 6Department of Gastroenterology & Hepatology and Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 7Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway. Mette Vesterhus and Johannes R. Hov jointly supervised this work. Correspondence and requests for materials should be addressed to J.R.H. (email: j.e.r.hov@medisin.uio.no)

Received: 10 December 2018
Accepted: 14 May 2019
Published online: 11 June 2019
two independent Norwegian PSC panels, and explore the role of autotaxin as a potential biomarker for cancer development as well as associations with other novel biomarkers.

Patients and Methods
Patient population and data collection. In the discovery panel, 165 patients (74% male) with large-duct PSC were included, while the validation panel comprised 87 patients with large-duct PSC (82% male). Detailed demographic data for both panels can be found in Table 1. The median observation time was 6.58 years (range 0.01–24.36) from time of sampling for the merged panel.

Diagnosis of PSC was based on typical findings on magnetic resonance cholangiography or endoscopic retrograde cholangiography according to established criteria15. Patients were recruited at admission to Oslo University Hospital Rikshospitalet in the period from 1992–2006 in the discovery panel and 2008–2011 in the validation panel. Regarding the end-point of liver transplantation or death, patients were followed until 31st of December 2016. Blood samples were included into the Norwegian PSC Research Centre (NoPSC) Biobank (Oslo, Norway). The first cholangiography compatible with PSC defined the time of diagnosis. Duration of disease was defined as the time from diagnosis to serum sampling. Clinical and demographic information was acquired from patient records and research databases, including laboratory data, history of ascites, encephalopathy, variceal bleeding, inflammatory bowel disease, colorectal or hepatobiliary malignancy and medication at the time of serum extraction. Inflammatory bowel disease was diagnosed based on endoscopic and histological findings, according to accepted criteria16. Cause of death was extracted from the Cause of Death Registry (Oslo, Norway, reference 16–0230). Revised Mayo risk score was calculated according to the established algorithm17, in addition to Model for End-Stage Liver Disease (MELD) score 18 and Aspartate aminotransferase (AST) to Platelet Ratio Index (APRI) score, all calculated from data at sample time19.

In-house ELF score. Commercial kits were used to analyze serum levels of TIMP-1 and hyaluronic acid (both R&D Systems), and intact N-terminal PIIINP was analyzed by radioimmunoassay (UniQ PIIINP RIA; Orion Diagnostica, Espoo, Finland) in frozen serum samples. Inter- and intra-assay coefficients of variation were <10%. The algorithm used in the ADVIA Centaur XP ELF test, combining TIMP-1, hyaluronic acid, and PIIINP values, was subsequently used to calculate in-house ELF scores (ELF score = 2.278 + 0.851 ln(C_hyaluronic acid) + 0.751 ln(C_PIIINP) + 0.934 ln(C_TIMP1)).

Autotaxin activity assay. Stored sera, from sample time, thawed up to two times were analyzed for autotaxin activity by a fluorometric enzymatic assay. Autotaxin activity was quantified in (at least 20-fold diluted) sera. Briefly, serum samples were incubated with a buffer containing 500 mmol/L of NaCl, 5 mmol/L of MgCl₂, 100 mmol/L of Tris (pH = 9.0), and 0.05% Triton X-100 for 60 minutes at 37 °C. Parallel incubations were performed in the presence and absence of 1 mmol/L of LPC (14:0). Subsequently the amount of liberated choline

|                         | Discovery panel | Validation panel | P  |
|-------------------------|-----------------|------------------|----|
| Males, n (%)            | 122 (74)        | 71 (82)          |    |
| Age at sampling, years, median (range) | 40.98 (13.23–75.50) | 38.48 (16.33–63.47) | 0.866 |
| Age at diagnosis, years, median (range) | 34.06 (13.22–70.09) | 34.30 (14.48–62.22) | 0.821 |
| PSC duration, years, median (range) | 1.08 (−0.15–22.39) | 0.72 (−0.59–28.95) | 0.328 |
| IBD ever, n (%)         | 137 (83)        | 68 (78)          | 0.037 |
| Follow-up, years, median (range) | 4.33 (0.01–24.36) | 6.77 (0.04–8.35) | 0.335 |
| Liver transplantation as end-point, n (%) | 86 (52) | 27 (31) |   |
| Death as end-point n, (%) | 32 (19) | 8 (9) |   |
| Mayo risk score, median (range) | 0.73 (−2.24–5.26) | 0.07 (−2.10–3.28) | 0.005 |
| ELF-score, median (range) | 11.14 (7.67–14.29) | 10.67 (7.86–14.11) | 0.004 |

Laboratory data

|                         | Discovery panel | Validation panel | P  |
|-------------------------|-----------------|------------------|----|
| ALP, U/L, median (range) | 567 (70–3100) | 230 (51–1459) | <0.001 |
| ALT, U/L, median (range) | 108 (8.0–780) | 88 (14–885) | 0.107 |
| AST, U/L, median (range) | 100 (8.0–1012) | 65 (16–1219) | 0.014 |
| Albumin g/L, median (range) | 37 (15–50) | 41 (24–50) | <0.001 |
| Total bilirubin, µmol/L, median (range) | 31 (5–464) | 20 (4–532) | 0.012 |
| Creatinine, µmol/L, median (range) | 73 (41–216) | 68 (39–90) | <0.001 |
| Platelets 10⁹, median (range) | 233 (10–879) | 285 (56.7–819) | 0.008 |

Other information

|                         |                      |                  |    |
|-------------------------|----------------------|------------------|----|
| Gall bladder cancer, n (%) | 1 (0.6) | 0 |    |
| Cholangiocarcinoma, n (%) | 18 (11) | 8 (9) |    |
| Hepatocellular carcinoma, n (%) | 2 (1.2) | 0 |    |

Table 1. Demographic information for the two study panels. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATX, autotaxin; ELF, enhanced liver fibrosis; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis.
was determined by enzymatic fluorimetry using choline oxidase (2 U/mL), horseradish peroxidase (1.6 U/mL), and homovanillic acid as substrates for peroxidase. After the addition of both enzymes in a buffer (consisting of 20 mmol/L of CaCl₂, 2 mmol/L of HVA, 50 mmol/L of 3-[N-morpholino]propanesulfonic acid [pH = 8.0], and 0.1% Triton X-100), the increase in fluorescence was monitored at 37°C using a NOVOstar analyzer (excitation 320 nm and emission 405 nm; BMG Labtech GmbH, Offenburg, Germany). The (endogenous) amount of choline present in the sample without the addition of LPC was subtracted from the amount measured in the presence of LPC. Inter-assay variance was less than 15%, and intra-assay variance below 10%.

**Ethics.** The study was carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all study participants. The Regional Committee for Medical and Health Research Ethics of South-Eastern Norway approved the study (reference 2011/2572).

**Statistical analyses.** Data are presented as median (range) unless stated otherwise, except survival (in years) which is presented as mean (95% CI). When dichotomizing autotaxin levels in high/low categories, the previously published cutoff (>7.5 nmol mL⁻¹ min⁻¹) defined by Wunsch et al. was used14. Comparisons were done with Mann-Whitney U tests. Liver transplant-free survival was analyzed using Kaplan-Meier plots, and univariate and multivariate Cox regression. Variables with \( P < 0.05 \) in the univariate analysis were included in the final multivariate Cox regression model, except age, AST, bilirubin and albumin as they are included in Mayo risk score. The MELD score was highly right-skewed even after log-transformation and had a high rate of missing data; thus, we used the Mayo risk score in the Cox regression analyses. For correlations, Spearman's rank correlation test was applied. Statistical analyses were performed using SPSS (version 24; SPSS, Inc., Chicago, IL). P-values < 0.05 were considered statistically significant.

**Results**

**Patient characteristics.** There were 165 patients in the exploration panel and 87 in the validation panel. 74% and 82% of the patients were male, median age at sampling was 41.0 and 38.5 years, 83% and 78% had concomitant IBD, 52% and 31% underwent liver transplantation and 32% and 8% died during follow-up in the exploration and validation panel, respectively (Table 1). There was one (0.6%) case of gall bladder cancer and 2 cases of hepatocellular carcinoma (1.2%) in the exploration panel, 18 cases (11%) and 8 cases (9%) of cholangiocarcinoma in the exploration and validation panel, respectively.

**High autotaxin activity is associated with poor prognosis in PSC patients.** Mean autotaxin activity in the merged cohort (\( n = 252 \)) was 6.8 nmol mL⁻¹ min⁻¹ (standard deviation (SD) 3.7), lower in men, mean 6.3 nmol mL⁻¹ min⁻¹ (SD 3.0) than in women 8.6 nmol mL⁻¹ min⁻¹ (SD 4.9), \( P < 0.001 \). The activity was higher than previously reported in both male (2.5 nmol mL⁻¹ min⁻¹, SD 0.7) and female (3.2 nmol mL⁻¹ min⁻¹, SD 1.5) healthy controls20, \( P < 0.001 \) for both.

During follow-up, 118 (71.5%) and 35 (40.2%) patients reached an end-point, liver transplantation or death, in the discovery and validation cohorts, respectively. Patients who reached an end-point during follow-up showed higher ATX activity compared with the other patients in both cohorts (\( P < 0.001 \) and \( P < 0.004 \) in the discovery and validation cohort, respectively, Fig. 1a,b).

When stratifying patients according to autotaxin tertiles, there was a strong association between increasing autotaxin activity and shorter liver transplant-free survival in both cohorts (Fig. 1c,d). In a previous study, the optimal cut-off of autotaxin activity to distinguish patients with a higher risk of end-points was 7.5 nmol mL⁻¹ min⁻¹14. Repeating the analysis with this cut-off in the present study yielded similar results, with high autotaxin activity concentrations showing reduced liver transplant-free survival compared with the low autotaxin group in both cohorts (Fig. 1e,f, discovery panel: 3.90 years [2.30–5.50] vs. 11.79 [9.95–13.63], respectively, \( P < 0.001 \);

| | Discovery Panel | Validation Panel |
|---|---|---|
| | Mean (SD) | Mean (SD) |
| Autotaxin activity | 6.8 (3.7) | 7.5 (4.9) |
| Gender | 74% male | 82% male |
| Age (years) | 41.0 (14.9) | 38.5 (14.8) |

When stratifying patients according to autotaxin tertiles, there was a strong association between increasing autotaxin activity and shorter liver transplant-free survival in both cohorts (Fig. 1c,d). In a previous study, the optimal cut-off of autotaxin activity to distinguish patients with a higher risk of end-points was 7.5 nmol mL⁻¹ min⁻¹14. Repeating the analysis with this cut-off in the present study yielded similar results, with high autotaxin activity concentrations showing reduced liver transplant-free survival compared with the low autotaxin group in both cohorts (Fig. 1e,f, discovery panel: 3.90 years [2.30–5.50] vs. 11.79 [9.95–13.63], respectively, \( P < 0.001 \);

**Autotaxin activity** was similar in the discovery and validation panels, mean 6.6 nmol mL⁻¹ min⁻¹ (SD 3.6) and 7.2 nmol mL⁻¹ min⁻¹ (SD 3.8), respectively (\( P = 0.28 \)). Despite some baseline differences (Table 1), we therefore merged the discovery and validation panels to increase power when investigating the relationship between clinical and biochemical characteristics.

Significant positive correlations were observed between autotaxin and liver biochemistry (Table 2), with the strongest association observed for hirilrubin (rho: 0.376, \( P < 0.011 \)). ALP, AST and INR also correlated with autotaxin (rho = 0.16, 0.30, 0.21, respectively, all \( P < 0.05 \)), as well as C-reactive protein (rho = 0.17, \( P = 0.011 \)) while inverse correlations were noted with creatinine and albumin (rho = −0.323 and −0.404, respectively, both \( P < 0.001 \)).

Patients with impaired liver synthesis function as defined by INR ≥1.2 or Normotest <70 showed increased activity of autotaxin compared with patients with normal synthesis function, combined cohort: 7.69 (2.90–23.56)
vs. 5.50 (2.35–31.81), $P < 0.001$ (Fig. 2a). However, autotaxin was a good predictor of liver transplantation or death irrespective of liver synthesis function (Fig. 2b).

**Autotaxin activity and clinical characteristics.** In the merged cohort, 30 (11.9%) PSC patients were diagnosed with hepatobiliary malignancy during follow-up. Autotaxin activity was similar in patients who developed cancer during follow-up and those who did not (5.49 [2.90–11.35] vs. 5.81 [2.35–31.81], respectively, $P = 0.42$). There was also no difference in patients with and without IBD (5.89 [2.44–31.81] vs. 6.03 [2.44–22.75], respectively, $P = 0.90$), or between the different subtypes of IBD (data not shown). In a small subgroup $n = 32$, severity of disease using the cholangiography-based Amsterdam score was evaluated in a previous study\(^{21}\). Patients with advanced PSC had numerically higher autotaxin activity than mild PSC (8.9 vs. 7.7), but this was not statistically significant ($P = 0.51$).

Moderate significant correlations were found between autotaxin and PSC duration (rho = 0.184, $P = 0.003$), and clinical risk scores; Mayo risk score (rho = 0.408, $P < 0.001$) and MELD score (0.233, $P = 0.006$), also see Table 2. Data on ursodeoxycholic acid (UDCA) treatment was available for 86 patients from the validation cohort (99%), out of which 35 (41%) were treated at the time of sampling. Patients treated with UDCA had higher autotaxin levels compared to other patients (7.48 [3.83–23.93] vs. 5.50 [2.90–14.25], respectively, $P = 0.005$). However, Mayo risk scores and liver transplant-free survival were not significantly different between patients with and without UDCA treatment (Mayo risk score 0.18 (−2.10–3.28) vs. −0.04 (−2.09–3.20), respectively $P = 0.65$, and survival 5.0 (3.8–6.1) vs. 6.4 (5.6–7.3) years, respectively, $P = 0.055$).
correlated with autotaxin activity (95% CI 1.21–3.40), P < 0.001), the in-house ELF score and IL-8 (HR 2.03, 95% CI 1.28–3.19), P < 0.001). This suggests that markers of inflammation (IL-8) and liver fibrosis (ELF test) predict liver transplant-free survival in PSC, in line with the present data. Mechanistic studies of autotaxin in PSC are scarce. In PSC, reduced liver transplant-free survival for all markers (Fig. 4). Re-doing these analyses with liver-related deaths only, did not influence the results (data not shown).

Notably, Mayo risk score had a better ability to discriminate patients with and without liver transplantation or death during follow-up (AUC 0.81 vs. 0.66, P < 0.001, Fig. 5a). The same was apparent for in-house ELF (AUC 0.79, P < 0.001), but not IL-8 (AUC 0.71, P = 0.25), see Fig. 5b. However, when analyzed using Cox regression, high autotaxin as defined by the validated cut-off 7.5 nmol mL$^{-1}$ min$^{-1}$, as defined by Wunsch et al., high levels were associated with reduced liver transplant-free survival for all markers (Fig. 4).

Re-doing these analyses with liver-related deaths only, did not influence the results (data not shown).

Discussion

In this cross-sectional study of autotaxin activity in two independent cohorts of PSC patients, we found a strong correlation between increasing autotaxin and shorter liver transplantation-free survival. Autotaxin activity correlated with disease severity, as measured by Mayo risk score, but there was no association with IBD or cancer. Autotaxin correlated moderately with new biomarkers in PSC, including IL-8 and ELF-score, but in multivariate analyses high autotaxin was an independent predictor of liver transplant-free survival.

A key observation in the present study is that we show in two independent cohorts of in total 252 large-duct PSC patients that high autotaxin activity is associated with reduced liver transplantation-free survival with a moderate HR of 2.0 in multivariable regression, corroborating a previous finding by Wunsch et al., who investigated autotaxin in 115 PSC patients. Similar correlations between autotaxin activity and liver biochemistries and clinical parameters like Mayo risk score and MELD score were also seen. This highlights autotaxin activity as a biomarker of potential clinical value, in particular in combination with other markers. Its relationship with disease activity and response to treatment in drug trials should clearly be investigated to define its utility, in line with recent trials investigating markers of fibrosis.

The mechanisms causing elevated autotaxin activity in PSC are not clear. Autotaxin has been shown to predict survival, disease stage and cirrhosis also in non-cholestatic conditions, while the value of autotaxin as a serum marker of fibrosis varies between phenotypes, being a better predictor in viral hepatitis compared to non-alcoholic fatty liver disease. In other studies of viral hepatitis, autotaxin also correlates with liver stiffness measured with transient elastography. Autotaxin has also been reported to inversely correlate with albumin levels in chronic liver diseases, in line with the present data. Mechanistic studies of autotaxin in PSC are scarce. In murine models of fibrosis, increased autotaxin expression in hepatocytes has been observed both after liver injury caused by carbon tetrachloride and after viral infection. Genetic or pharmacological inhibition of autotaxin subsequently reduced liver fibrosis in the model, suggesting a direct link to fibrosis. However, whether hepatocyte expression can account for the increased autotaxin activity observed during cholestasis and cholestatic pruritus in PSC is not known. The negative correlation between autotaxin activity and albumin on the one hand, and positive correlation with INR on the other hand suggest that autotaxin activity is not affected by liver synthesis function. We also make the novel observation that autotaxin activity only moderately correlates with the new PSC biomarkers IL-8 and an in-house ELF, whereas autotaxin activity still independently predicts survival. This suggests that autotaxin is a marker of aspects of the PSC pathogenesis reflecting more than just inflammation or fibrosis.
fibrosis. Biomarkers of inflammation, fibrosis and pruritus might independently predict prognosis and underline the potential utility of multi-marker panels to account for the complexity of PSC. This should be investigated in subsequent studies.

Another important observation in the present study is the lack of correlation between autotaxin and biliary tract cancer. This is contradictory to studies describing an emerging role of LPA and autotaxin in malignant diseases, e.g. hematological malignancies and pancreatic cancer. Autotaxin has been proposed to be an important mediator in cancer cell growth and metastasis. It has also been speculated that it is a link between liver disease and cholangiocarcinoma (CCA), and there were no signs of association between autotaxin and biliary cancer in our cohort. One possible explanation is if autotaxin only reflects the presence of tumor without being able to predict later tumor development. Still, the observation contrasts other novel PSC biomarkers, which seem CCA-related. Examples include associations observed between CCA in PSC and elevated ELF, increased soluble CD14 and increased prevalence of IgA anti-GP2, providing further evidence of unique characteristics of autotaxin as biomarker.

A peculiar observation was the increased autotaxin activity observed in PSC patients receiving treatment with UDCA. Importantly, data on UDCA use was only available in the smaller validation cohort (n = 87) and an association does not imply causation. In the study by Wunsch et al., autotaxin activity was higher in PBC patients who did not respond to UDCA treatment, compared to other patients. It has been hypothesized that the lack of response to UDCA in some PBC patients may indicate a failure to upregulate alk-SMase, another nucleotide pyrophosphatase/phosphodiesterase (NPP) enzyme similar to autotaxin, by UDCA in these patients, leading to increased levels of autotaxin. A more likely hypothesis explaining increased autotaxin activity in UDCA-treated PSC patients in the present study may be that PSC patients in Norway usually receive UDCA only on specific indication, i.e. flares, pruritus or gallstones, and it may be that patients receiving UDCA had more pruritus or...
even more serious disease. However, it should be noted that measures of disease severity were not convincingly different in patients with and without UDCA (Mayo risk score and liver transplant-free survival).

The strengths of the present study are the large sample size, the inclusion of a validation cohort, and the long follow-up period, although the cross-sectional design makes us unable to make assumptions about cause end

Figure 4. Autotaxin and other established biomarkers in PSC. High autotaxin levels (>7.5 nmol mL\(^{-1}\) min\(^{-1}\) as defined by Wunsch et al.\(^{14}\)) are associated with poor survival in subgroups with both (a) low IL-8 values, and (b) high IL-8 values (divided by median). Similar, high autotaxin levels are associated with reduced liver transplant-free survival irrespective of (c) low ELF score or (d) high ELF-score (divided by median). ATX, autotaxin; ELF, enhanced liver fibrosis; IL, interleukin.

Figure 5. Comparison of autotaxin and other biomarkers in PSC. (a) Mayo risk score had a better ability to discriminate patients with and without liver transplantation or death during follow-up (AUC 0.81 vs. 0.66, \(P < 0.001\)), as had bilirubin (AUC 0.77 vs. 0.66, \(P < 0.001\)), while Mayo risk score and bilirubin were similar (\(P = 0.07\)). The same was apparent for the in-house ELF score (AUC 0.79, \(P < 0.001\)) but not IL-8 (AUC 0.71, \(P = 0.25\)) (panel b). AUC, area under the receiver operating characteristic curve; ELF, enhanced liver fibrosis; IL, interleukin; PSC, primary sclerosing cholangitis.
Autotaxin (high)\(^*\)  & 2.84 (2.05–3.94)  & 252  & 1.37 (1.24–1.53)  & 252  & 0.216  & 0.79 (0.53–1.14)  & 252  & 0.632  & 1.11 (0.72–1.72)  & 241  
Gender (male)  &  &  &  &  &  &  &  &  &  &  &  
Age at sample  &  &  &  &  &  &  &  &  &  &  &  
PSC duration  &  &  &  &  &  &  &  &  &  &  &  
IBD (yes)  &  &  &  &  &  &  &  &  &  &  &  
Hepatobiliary cancer (yes)  &  &  &  &  &  &  &  &  &  &  &  
Mayo risk score  &  &  &  &  &  &  &  &  &  &  &  
In-house ELF score  &  &  &  &  &  &  &  &  &  &  &  
ALP\(^*\)  & 1.42 (1.17–1.73)  & 219  & 0.929  & 0.99 (0.84–1.17)  & 233  
ALT\(^*\)  &  &  &  &  &  &  &  &  &  &  &  
AST\(^*\)  & 1.39 (1.15–1.67)  & 232  
Albumin  & 0.89 (0.87–0.91)  & 221  
Total bilirubin\(^*\)  & 0.81  & 1.82 (1.58–2.08)  & 232  
Creatinine  & 0.801  & 1.00 (0.98–1.01)  & 214  
Platelets\(^*\)  & 0.67 (0.54–0.84)  & 205  
Impaired liver synthesis function (yes)\(^*\)  & 3.09 (2.16–4.42)  & 209  
CRP > 10 (yes)  & 3.89 (2.72–5.57)  & 213  
IL–8\(^*\)  & 1.37 (1.24–1.53)  & 252  

Table 3. Cox regression analysis in the combined panel (n = 252). *All variables with P < 0.05 in the univariate analysis were included in the multivariate model, except age, AST, bilirubin and albumin as they are included in the Mayo risk score. Complete data for all variables in the model were available for n = 157 patients in the combined panel. †Autotaxin >7.5 nmol mL\(^−1\) min\(^−1\) as defined by Wunsch et al.\(^{14}\). ‡Defined as INR ≥ 1.2 or Normotest < 70. PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease; ELF, enhanced liver fibrosis; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CRP, C–reactive protein; IL, interleukin; HR, hazard ratio.

Data Availability
The dataset used in the present study is available from the corresponding author on reasonable request.

References
1. de Vries, E. M. et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut, https://doi.org/10.1136/gutjnl-2016-313681 (2017).
2. Weisnmueller, T. J. et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, https://doi.org/10.1053/j.gastro.2017.02.038 (2017).
3. Kremer, A. E. et al. Pathogenesis and Management of Pruritus in PBC and PSC. Digestive diseases (Basel, Switzerland) 33(Suppl 2), 60–157, https://doi.org/10.1159/000440629 (2015).
4. Kremer, A. E. et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139, 1088–1014, 1018 e1001, https://doi.org/10.1053/j.gastro.2010.05.009 (2010).
5. Beuers, U., Kremer, A. E., Bolier, R. & Elferink, R. P. Pruritus in cholestasis: facts and fiction. Hepatology (Baltimore, Md.) 60, 399–407, https://doi.org/10.1002/hep.26909 (2014).
6. Mills, G. B. & Moosevzt, W. H. The emerging role of lysophosphatidic acid in cancer. Nature reviews. Cancer 3, 582–591, https://doi.org/10.1038/nrc1143 (2003).
7. Leblanc, R. & Peyruchaud, O. New insights into the autotaxin/LPA axis in cancer development and metastasis. Experimental cell research 333, 183–189, https://doi.org/10.1016/j.yexcr.2014.11.010 (2015).
8. Ikeeda, H. & Yamotomi, Y. Autotaxin in liver fibrosis. Clinica chimica acta; international journal of clinical chemistry 413, 1817–1821, https://doi.org/10.1016/j.cca.2012.07.014 (2012).
9. Zwarens, S. J. et al. Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis. Liver Int 36, 1370–1377, https://doi.org/10.1111/liv.13092 (2016).
10. Dhillon, A. K. et al. Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis. Liver international: official journal of the International Association for the Study of the Liver, https://doi.org/10.1111/liv.13979 (2018).
11. de Vries, E. M. G. et al. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. *Liver Int* **37**, 1554–1561, https://doi.org/10.1111/liv.13402 (2017).
12. Kummer, M. et al. The gut microbiota profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. *Gut* **66**, 611–619, https://doi.org/10.1136/gutjnl-2015-310500 (2017).
13. Kummer, M. et al. Elevated trimethylamine–N–oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function. *United European Gastroenterol J* **5**, 532–541, https://doi.org/10.1177/2050604616664353 (2017).
14. Wünsch, E. et al. Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases. *Sci Rep* **6**, 30847, https://doi.org/10.1038/srep30847 (2016).
15. Chapman, R. et al. Diagnosis and management of primary sclerosing cholangitis. *Hepatology* **51**, 660–678, https://doi.org/10.1002/hep.23294 (2010).
16. Lennard-Jones, J. E. Classification of inflammatory bowel disease. *Scand. J. Gastroenterol. Suppl.* **170**, 2–6 (1989).
17. Kim, W. R. *Classification of inflammatory bowel disease.* Mayo Clin. Proc. **75**, 688–694, https://doi.org/10.4065/75.7.688 (2000).
18. Lin, Z. H. et al. A model to predict survival in patients with end-stage liver disease. *Hepatology* **33**, 464–470, https://doi.org/10.1001/jhep.2001.22172 (2001).
19. Lin, Z. H. et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C–related fibrosis: an updated meta-analysis. *Hepatology (Baltimore, Md.)* **53**, 726–736, https://doi.org/10.1002/hep.24105 (2011).
20. Kremer, A. E. et al. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. *J. Hepatol.* **62**, 897–904, https://doi.org/10.1016/j.jhep.2014.10.041 (2015).
21. Vesterhus, M. et al. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. *J. Hepatol.*, https://doi.org/10.1016/j.jhep.2017.01.019 (2017).
22. Vesterhus, M. et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. *Hepatology (Baltimore, Md.)* **62**, 188–197, https://doi.org/10.1002/hep.27825 (2015).
23. Nakamura, K. et al. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. *Hepatology*, https://doi.org/10.1002/hep.30237 (2018).
24. Hirschfield, G. M., Karlsen, T. H., Lindor, K. D. & Adams, D. H. Primary sclerosing cholangitis. *Lancet* **382**, 1587–1599, https://doi.org/10.1016/S0140-6736(13)60996-3 (2013).
25. Plei, T. et al. Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis—a prospective cohort study. *PLoS One* **9**, e103532, https://doi.org/10.1371/journal.pone.0103532 (2014).
26. Ikeda, H. et al. Performance of autotaxin as a serum marker for liver fibrosis. *Annals of clinical biochemistry* **55**, 469–477, https://doi.org/10.1177/0004563217741509 (2018).
27. Nakagawa, H. et al. Autotaxin as a novel serum marker of liver fibrosis. *Clin. Chim. Acta* **412**, 1201–1206, https://doi.org/10.1016/j.cca.2011.03.014 (2011).
28. Nakamura, K. et al. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. *Clinica chimica acta; international journal of clinical chemistry* **388**, 51–58, https://doi.org/10.1016/j.cca.2007.10.005 (2008).
29. Kaffe, E. et al. Hepatocyte autotaxin expression promotes liver fibrosis and cancer. *Hepatology (Baltimore, Md.)* **65**, 1369–1383, https://doi.org/10.1002/hep.28973 (2017).
30. Masuda, A. et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. *British journal of haematology* **143**, 60–70, https://doi.org/10.1111/j.1365-2141.2008.07325.x (2008).
31. Nakai, Y. et al. Specific increase in serum autotaxin activity in patients with pancreatic cancer. *Clinical biochemistry* **44**, 576–581, https://doi.org/10.1016/j.clinbiochem.2011.03.128 (2011).
32. Cooper, A. B., Wu, J., Lu, D. & Maluccio, M. A. Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer? *Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract* **11**, 1628–1634; discussion 1634–1625, https://doi.org/10.1007/s11605-007-0322-9 (2008).
33. Kondo, M. et al. Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma. *Clinica chimica acta; international journal of clinical chemistry* **433**, 128–134, https://doi.org/10.1016/j.cca.2014.03.006 (2014).
34. Jendrek, S. T. et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. *Gut* **66**, 137–144, https://doi.org/10.1136/gutjnl-2016-311739 (2017).
35. Duan, R. D. Alkaline sphingomyelinase (NPP7) in hepatobiliary diseases: A field that needs to be closely studied. *World journal of hepatology* **10**, 246–253, https://doi.org/10.4254/wjh.v10.i2.246 (2018).

**Acknowledgements**
AKD and JRH are funded by the Research Council of Norway (no. 240787/F20). MK is funded by the Regional Health Authority of South-Eastern Norway (no. 2016067). This work was supported by the German Research Foundation to AEK (KR4391/1-1, KR3618/3-1) and interdisciplinary center for clinical research (IZKF) at the Friedrich-Alexander-University of Erlangen-Nürnberg to AEK.

**Author Contributions**
Contributors J.R.H., U.B., T.H.K., R.P.O.E., A.E.K. and M.V. planned the study. K.M.B. contributed to collection of samples and clinical data. A.E.K. performed the autotaxin analyses. A.K.D., M.K. and J.R.H. planned, performed and interpreted the statistical analyses. A.K.D. wrote the initial draft, and M.K. and J.R.H. contributed to the writing of the manuscript. All authors read and critically revised for important intellectual content and approved the final manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
